-
On the company's conference call, Jami Rubin at Morgan Stanley complained that Schering's guidance on Vytorin and Zetia sales amounts basically to saying they will go down.
FORBES: Magazine Article
-
Jami Rubin, the pharmaceuticals analyst at Morgan Stanley, points to Merck's healthy balance sheet.
FORBES: Magazine Article
-
Jami Rubin, the pharmaceuticals analyst at Morgan Stanley (nyse: MS - news - people ), points to Merck's healthy balance sheet.
FORBES: Forget Vioxx?